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ABSTRACT 
 
OBJECTIVE The post nasal drip is a very common symptom of 
sinusitis, allergic rhinosinusopathy, the gastroesophageal reflux disease, 
but there are some patients, who have a post nasal drip, sensation of a 
foreign body in the nasopharynx and a non-specific irritant cough with 
no others symptoms or signs of sinus inflammations or allergy. In the 
posterior rhinoscopy mucus discharge is seen. Ethiology and patho-
genesis of this syndrome evolution are still unclear. The aim of the study 
was to identify the neuropeptide appearance and distribution in nasal and 
nasopharyngeal mucosa in the patients with the isolated post nasal drip 
syndrome and the control group, for the comparison of the data.  
MATERIALS AND METHODS. We investigated the biopsies of 
nasal and nasopharyngeal mucosa from 11 adult patients, who had the 
isolated post nasal drip syndrome and from 2 control group patients 
without post nasal drip, by conventional light microscopy and 
immunohistological techniques for the protein gene product 9.5 (PGP), 
Neuropeptide Y (NPY), serotonin, Substance P (SP), vasoactive intes-
tinal peptide (VIP), Calcitonin gene related peptide (CGRP) and 
Chromogranin A (CgA). 
RESULTS. The conventional light microscopy showed a very thick 
basal membrane, the sclerosis of small blood vessels, the hyperplasia of 
mucosal glands- the neurogenic inflammation, mostly in nasopharyngeal 
mucosa. The abundance of PGP-containing nerve fibres was found 
around glands, sclerotic arterioles in almost all the cases. The main 
neuropeptides that were found in the mucosa of the patients were VIP, 
NPY, CgA, mostly in the nasopharyngeal mucosa. There were diffe-390  G. Sumeraga, M. Pilmane 
rences in PGP-containing structures and the selective neuropeptide 
(NPY, CgA, and VIP) distribution in nasal and nasopharyngeal mucosa 
in comparison with the control group.  
CONCLUSIONS. The main histological changes in the patients with 
the isolated post nasal drip syndrome are a thickened basal membrane, 
the hyperplasia of basal cells, pronounced hyperplasia of mucosal 
glands, the sclerosis of small arterioles. The main neuropeptides that are 
found in nasal and nasopharyngeal mucosa samples are PGP 9.5, 
vasoactive intestinal peptide, neuropeptide Y and chromogranin in the 
post nasal drip syndrome group.  There is an imbalance of common 
neuropeptide-containing innervations, mainly sympathic nerves, the 
precursors of neuropeptides- chromogranins in the nasopharyngeal 
mucosa of the patients with the post nasal drip syndrome. SP and CGRP 
are not the most characteristic neuropeptides in the case of the post nasal 
drip syndrome pathogenesis.  
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INTRODUCTION 
The post nasal drip is usually a symptom of acute or chronic rhino-
sinusitis, allergic rhinosinusitis, gastroesophageal reflux disease. There 
is a group of patients, who have no other symptoms of sinus inflam-
mation, allergy or reflux, but still they have mucus discharge in naso-
parynx, the sensation of a foreign body in the pharynx and irritant 
cough, the so-called post nasal drip syndrome (23). 
The nasal mucosa is richly innervated by sensory, sympathetic and 
parasympathetic nerve fibres which secrete, when they become acti-
vated, a variety of transmitter molecules. The source of neuropeptides 
may be the nerve cells and the neurons associated cells, like glyocytes 
and fibroblasts. C and Aδ fiber stimulation causes the release of neuro-
peptides. The release of neuropeptides by sensory nerve endings pro-
duces vasodilatation and increased vascular permeability, the pheno-
mena primarily described in the rodents that have been collectively 
termed neurogenic inflammation (4, 16, 22).  
The substance P (SP), serotonin, the calcitonin gene related peptide 
(CGRP), the gastrine releasing peptide, the neuropeptide Y (NPY), the 
vasoactive intestinal peptide (VIP), chromogranin are found in nasal 
mucosa (4). These neuropeptides cause vasodilatation and upper airways  Distribution of neuropeptides in nasal and nasopharyngeal mucosa ...  391 
 
oedema, characterized by nasal obstruction, and bronchial constrictions, 
increased mucus formation, the leukocyte recruitment and differen-
tiation and the activation of various immune cells, including 
lymphocytes, eosinophils, mast cells, and macrophages (23, 24).  
In the case of chronic upper and lower respiratory tract illnesses, 
respiratory mucosa shows an increased quantity of pro-inflammatory 
sensory neuropeptides. Neuropeptide concentrations correlate with the 
patients’ symptom intensity (16). 
The concentration of neuropeptides in the bronchial and nasal 
secretions is relatively low for asymptomatic patients, but it is highly 
elevated in the patients with allergic respiratory diseases, including nasal 
polyps (4, 7). Since neuroendocrine cells in the airway mucosa are 
discovered, increasing interest is attached to the yet unexplored 
neurogenic inflammation in the case of chronic airway inflammation, 
especially if it is characterized by increased airway reactivity.  
The aim of the study was to identify neuropeptide appearance and 
distribution in nasal and nasopharyngeal mucosa in the patients with the 
isolated post nasal drip syndrome and the patients without the post nasal 
drip and to compare the data.  
 
MATERIAL AND METHODS 
Inferior nasal turbinate and nasopharyngeal mucosa specimens were 
obtained from 11 adult patients (age 18–58) with the isolated post nasal 
drip syndrome and from 2 control group patients (age 28–36).  
All the patients were examinated by an otolaryngologist to exclude 
rhinosinusopathy (the normal pneumatisation of all the sinuses at the CT 
scan), allergy (no changes in skin prick tests, IgE range (total and 
specific)) and gastroesophageal reflux disease (clinically and by per-
forming endofibrogastroscopy). All the patients have had symptoms of 
the post nasal drip for more than 6 months and had no reaction to 
common therapy: topical steroid (fluticasone), antihistamine (loratidin), 
anti-reflux therapy (diet and omeprasole).  
The control group was formed from 2 voluntary patients, who where 
undergoing rhinoseptoplasty, these patients where without any 
symptoms of the post nasal drip.  
Tissue pieces (1–2 mm²) from the middle part of the lower nasal 
turbinate and the middle part of the nasopharyngeal arch area were taken 392  G. Sumeraga, M. Pilmane 
under control of the endoscope, under local anaesthesia (submucosal 
administration of 1–2 ml of 1% lidocaine solution) or general 
anaesthesia (control group).  
For immediate fixation previously prepared saturated picric acid 
solution (formaldehyde 2%, 0.2%o Picric acid, 1 M phosphate buffered 
(pH 7.2) was used. Tissue slices were stained with haematoxylin and 
eosin, and by the use of immunohistological technique (Hsu et al 1981) 
for the protein gene product 9.5 (PGP), substance  P (SP), Neuro-
peptide  Y (NPY), vasoactive intestinal peptide (VIP), serotonin, 
calcitonin gene related peptide (CGRP) and chromogranin A (CgA) 
(Table 1). 
The samples were examined under the Leica microscope. The results 
of immunohistochemistry were listed by the semi-quantitative counting 
method (Tobin et al., 1990; Pilmane, 1997) (Table 2). 
 
Table 1. The data of the antibodies applied in immunohistochemistry 
 Obtained 
from 
Working 
dilution 
Manufacturer  Code 
PGP rabbit  1:600  DAKO  (Denmark) Z5116 
Serotonin mouse  1:10  DAKO  (Denmark)  M758 
NPY rabbit  1:10  DAKO  (Denmark)  B48-100 
VIP rabbit  1:400  abcam  (UK)  Ab22736 
SP mouse  1:1000  abcam  (UK)  Ab14184 
CGRP rabbit  1:20 Quartet  (Germany)  281328 
CgA rabbit  1:400  DAKO  (Denmark) A0430 
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Table 2. The semi-quantitative analysis of the immunohistochemically 
determined structures 
Applied 
markings  Semiquantitive explantation 
–  No positive structure seen in the visual field 
0/+  Rare positive structures seen in the visual field 
+  Few positive structures seen in the visual field 
+/++  Few to a moderate number of positive structures seen in the 
visual field 
++  A moderate number of positive structures seen in the visual 
field 
++/+++  Moderate to numerous positive structures seen in the visual 
field 
+++ Numerous  positive  structures seen in the visual field 
+++/++++  The abundance of positive structures in the visual field 
 
RESULTS 
Nasal mucosa demonstrated the pronounced partially patchy thickened 
basal membrane. Epithelium showed basal cell hyperplasia and 
intraepithelial infiltration with lymphocytes, marked hyperplasia of 
glandulocytes was seen along the epithelial lining (Figure 1). Two of the 
patients showed the metaplasia of the epithelium (the stratified 
squamous epithelium instead of the pseudostratified ciliated epithelium). 
Lamina propria also demonstrated infiltration with lymphocytes, the 
hypertrophy of glands and the sclerosis of small arterioles (Figure 2). 
One patient showed the granulation tissue of subepithelium and marked 
infiltration of lymphocytes, and another patient had the lymphatic 
nodule of the subepithelium.  
The control group patients’ nasal mucosa samples where without 
marked inflammation – no lymphocyte infiltration was seen, sero-
mucosal glands where without hyperplasia.  
Numerous PGP-containing nerve fibres (+++) were observed mainly 
around the secretory parts of seromucosal glands and sclerotic arterioles 
(Figure 3). The patient with lymphatic nodules in the submucosa 
demonstred an occasional amount of PGP-containing nerve fibres. The 
patient who had granulations and the methaplasia of nasal epithelium, 394  G. Sumeraga, M. Pilmane 
showed almost negative PGP structures in all the mucosa samples (0/+) 
(Table 3). 
The control group patientsʼ nasal mucosa samples showed moderate 
(++) PGP-containing nerve fibres, mostly around blood vessels and 
seromucosal glands (Table 4). 
Nasopharyngeal mucosa showed even more expressed changes in 
comparison to nasal mucosa – the very thickened basal membrane, the 
hyperplasia of basal cells, the pronounced hyperplasia of mucosal 
glands, the sclerosis of small arterioles, some patients had infiltrations of 
lymphocytes in the submucosa. One patient, the same with granulations 
in the nasal mucosa, also showed the granulation tissue in the naso-
pharyngeal submucosa. One of the control group patients had mucoid 
respiratory epithelium in the nasopharynx, another one had normal 
respiratory epithelium in the nasopharynx without marked inflammation 
or hyperplasia.  
 
Table 3. The results of immunohistochemical findings in nasal and naso-
pharyngeal mucosa 
  PGP NPY VIP SP  CGRP Sero-
tonin CgA 
Glands – nasal 
mucosa 
++/+++  0/+ ++  0/+ 0/+  –  +++ 
Glands – 
nasopharyngeal 
mucosa 
 
++/+++  + ++  0/+ 0/+ – +++ 
Blood vessels – 
Nasal mucosa 
++/+++  0/+ ++  0/+ 0/+  –  ++ 
Blood vessels – 
Nasopharyngeal 
mucosa 
+++  +  ++  0/+ 0/+ –  ++/+++ 
Total ++/+++  +  ++  0/+ 0/+  –  ++/+++ 
(–) No positive structure seen in the visual field, (0/+) rare positive structures seen in 
the visual field, ( + ) Occasionally positive structures seen in the visual field, (+/++) 
few to moderate number of positive structures seen in the visual field, (++) a 
moderate number of positive structures seen in the visual field, (++/+++) moderate 
to numerous positive structures seen in the visual field, (+++) numerous positive 
structures seen in the visual field, (+++/++++) the abundance of positive structures 
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Table 4. The results of immunohistochemical findings in nasal and 
nasopharyngeal mucosa – the control group 
  PGP NPY VIP SP CGRP Sero- 
tonin  CgA 
Glands – nasal mucosa  ++  0/+  0/+  0/+  0/+  –  + 
Glands – 
nasopharyngeal mucosa 
++ 0/+  0/+  0/+ 0/+  –  + 
Blood vessels – 
Nasal mucosa 
++ 0/+  0/+  0/+ 0/+  –  + 
Blood vessels – 
Nasopharyngeal mucosa 
++ 0/+  0/+  0/+ 0/+  –  + 
Total ++  0/+  0/+  0/+  0/+  –  + 
(–) No positive structure seen in the visual field, (0/+) rare positive structures seen in 
the visual field, ( + ) Occasionally positive structures seen in the visual field, (+/++) 
few to moderate number of positive structures seen in the visual field, (++) a 
moderate number of positive structures seen in the visual field, (++/+++) moderate 
to numerous positive structures seen in the visual field, (+++) numerous positive 
structures seen in the visual field, (+++/++++) the abundance of positive structures 
in the visual field.  
 
 
Figure 1. The marked hyperplasia of seromucosal glands, the infiltration of 
lymphocytes in nasal mucosa, HE x 200.  396  G. Sumeraga, M. Pilmane 
 
Figure 2. Sclerotic small arterioles, the hyperplasia of seromucosal glands 
and the infiltration of lymphocytes in nasopharyngeal mucosa. HE x 200. 
 
 
Figure 3. The abundance of PGP immunopositive structures around 
sclerotic arterioles and hyperplased seromucosal glands in nasopharyngeal 
mucosa. PGP 9.5 x 200.  Distribution of neuropeptides in nasal and nasopharyngeal mucosa ...  397 
 
 
Figure 4. VIP containing nerve fibres around blood vessels in naso-
pharyngeal mucosa. VIP x200. 
 
 
Figure 5. Numerous Chromogranin A granules containing cells next to the 
hyperplased seromucosal glands. CgA x250. 398  G. Sumeraga, M. Pilmane 
The abundance of PGP-containing nerve fibres (+++/++++) was found 
around glands, sclerotic arterioles in almost all the samples, except the 
patient with granulations in sub mucosa – he had only few PGP-
containing fibres (+) and only next to some seromucos glands (Figure 4) 
(Table 3). 
The control group patients demonstrated moderate PGP immuno-
positive structures (++) in nasopharyngeal mucosa, mostly next to 
seromucosal glands and arterioles.  
All the nasal and nasopharyngeal mucosa samples, also in the control 
group, were serotonin negative (Table 4). 
Most of the nasal and nasopharyngeal mucosa samples showed few 
NPY positive structures (+), mostly around small sclerotic arterioles in 
the nasopharyngeal mucosa. Exceptions were mucosal samples from the 
patient with lymphatic nodules in the submucosa, in this case we saw 
more positive structures in comparison to other patients’ mucosa 
samples around the arterioles in nasopharyngeal mucosa (++) (Table 3). 
The control group patientsʼ nasal and nasopharyngeal mucosa 
showed occasional NPY immunopositive structures (+) next to sero-
mucosal glands and blood vessels (Table 4). 
Nasal mucosa showed moderate to a large number of VIP-containing 
nerve fibres (++/+++) around submucosal glands and small sclerotic 
arterioles, but in the nasopharyngeal mucosa samples VIP-containing 
nerve fibres were even more, especially around sclerotic arterioles 
(++/+++) (Figure 5) (Table 3). The control group patients’ nasal and 
nasopharyngeal mucosa samples showed few VIP immunopositive 
structures mostly around blood vessels, similarly in nasal and naso-
pharyngeal mucosa (Table 4).  
In all the nasal and nasopharyngeal mucosa samples, including the 
control group patients, rare (0/+) or negative Substance P containing 
structures were found (Table 3) (Table 4). 
Occasional CGRP positive structures (0/+) in the visual field were 
seen in the nasal and nasopharyngeal mucosa, mainly in the naso-
pharyngeal mucosa next to blood vessels and around seromucosal 
glands, the same findings were seen in the control group patientsʼ 
mucosa samples (Table 3) (Table 4).  
Almost in all of nasal and nasopharyngeal mucosa samples moderate 
to numerous (++/+++) CgA-containing cells were found, mainly in 
seromucosal glands and the basal layer of epithelium (Figure 6) 
(Table 3). Moderate CgA immunopositive structures were found in the  Distribution of neuropeptides in nasal and nasopharyngeal mucosa ...  399 
 
control group nasal and nasopharyngeal mucosa samples next to blood 
vessels and glands (Table 4).  
 
DISCUSSION 
This study shows the infiltrations of lymphocytes, thick basal membrane 
and sclerotic small arterioles and the hyperplasia of seromucosal glands 
in the nasal and nasopharyngeal mucosa of the patients with the post 
nasal drip syndrome in contradistinction to the control group patients, 
whose nasal and nasopharyngeal mucosa samples showed no marked 
signs of chronic inflammation. Similar results describe also Stephanie 
and Kunal (2008) by the histological examination of nasal mucosa in the 
case of allergic rhinosinusitis and hyperreflectoric rhinitis (24).  
In the nasopharyngeal mucosa PGP-containing neural fibres were 
more observed than in the nasal mucosa (in the control group as well as 
in the post nasal drip patients group), probably due to the density of 
innervations, which is more pronounced in the mucosa of nasopharynx 
compared with the mucosa of lower nasal turbinate (3, 7, 24). PGP 
imunopositive structures were found less in the control group patients’ 
mucosa samples; probably this finding can be associated with the 
increased production of neuropeptides in the case of post nasal drip. 
Fisher & al (2005) describe similar histological findings and the 
abundance of PGP-containing nerve fibres in nasal mucosa in the case 
of persistent perennial allergic rhinitis (9), so we can not exclude some 
analogy with allergic inflammation in the case of the post nasal drip 
syndrome pathogenesis.  
VIP-containing nerve fibres are usually located around arterioles, 
glands, and muscle fibres and the most important effects of VIP are 
vasodilatation, bronchodilatation and the activation of glandular 
secretion (9). Our study showed moderate to a large number of VIP-
containing nerve fibres around seromucosal glands and small sclerotic 
arterioles, especially in the nasopharyngeal mucosa samples, it suggests 
that VIP could implicate in the pathogenesis of mucus discharge in the 
nasopharynx and probably also stimulate the sclerotisation. Especially 
according to the fact, that the control group patientsʼ nasal and 
nasopharyngeal mucosa samples contained a smaller (occasionaly to 
few) number of VIP imunopositive structures and there were no 
sclerotic arterioles (11, 12, 20).  400  G. Sumeraga, M. Pilmane 
In our study just rare NPY positive structures were found in nasal 
and nasopharyngeal mucosa. The control group patientsʼ nasal and 
nasopharyngeal mucosa samples contained rare NPY immunopositive 
structures. Heppt & al (2004) describes similar results in the patients 
with environmentally triggered hyperreflectory rhinitis (10). Neuro-
peptide Y is co-localized with norepinephrine in a population of 
sympathetic neurons in the walls of human nasal mucosal arterioles (4). 
Sympathetic stimulation induces vasoconstriction and increased nasal 
airway potency. There is also some evidence that sympathetic activity 
can induce airway glandular secretion through the stimulation of serous 
cells through β receptors (4, 19). There are studies that reported about 
the NPY effect on vasoconstriction, it is effective at reducing the 
symptoms of nasal obstruction and the weight of mucus secretions after 
the nasal allergen challenge (24). In this case, our findings explain 
increased mucus formation in the patients’ nasopharyngeal mucosa.  
In our study we investigated the substance P appearance in nasal and 
nasopharyngeal mucosa. The results showed rare or negative (0/+) SP 
containing structures, also in the control group patientsʼ mucosa. 
Sensory nerve neuropeptides include the tachykinins (i.e., substance P 
and neurokinin A), the calcitonin gene-related peptide (4, 23). The 
effects  of these neuropeptides include glandular activation, leukocyte 
recruitment, differentiation and the activation of various immune cells, 
including lymphocytes, eosinophils, mast cells and macrophages (15, 
24, 25). According to these known effects, it is unusual that the 
substance P was not found in nasal and nasopharyngeal mucosa 
samples, and the acquired results may suggest that the substance P is not 
so deeply involved in the pathogenesis of the post nasal drip syndrome.  
Our results showed the absence of serotonin in all the nasal and 
nasopharyngeal mucosal samples and also in the control group patients. 
Serotonin effects are smooth muscle contraction, vasodilatation, and 
increased vascular permeability. Serotonin as well as histamine, 
leukotrienes, prostaglandins and tryptase are released and account for 
the immediate airway allergy symptoms and it is often found in the case 
of hyperreflectoric rhinitis as well (9). That fact can suggest that 
serotonin as well as the substance P, has no significant influence on the 
post nasal drip pathogenesis, and it makes a significant difference from 
the described study results until now in the case of allergic and 
hyperreflectory rhinitis (7, 8, 9,10, 16).  Distribution of neuropeptides in nasal and nasopharyngeal mucosa ...  401 
 
In the studies described in literature, CGRP is usually found in 
allergic and hyperreflectoric rhinitis (16, 20). Calcitonin gene-related 
peptide is one of the neuropeptides that is released in the human nasal 
mucosa after trigeminal nerve stimulation. The main effects of this 
neuropeptide are vasodilatation, mucus secretion, plasma extravasations; 
CGRP exerted also a significant dose-dependent stimulation on ciliary’s 
beat frequency (4). According to these known effects the negative 
CGRP-containing nerve fibre in the present study is inexplicable. That 
seemly suggests the difference between the allergic and the neurogenic 
inflammation.  
Chromogranin A belongs to the granin family of uniquely acidic 
secretory proteins co-stored and co-secreted with other hormones and 
peptides in the elements of the diffuse neuroendocrine system. In nasal 
mucosa chromogranin mediates as a marker of neuropeptides, neuro-
endocrine cells. CgA peptides take part in the regulation of calcium and 
glucose metabolism, cardiovascular functions, gastrointestinal motility 
and nociception, tissue repair, inflammatory responses and as host 
defence peptides in the first phase of microbial invasions (4, 26, 27). 
Our results showed moderate to numerous CgA immunopositive cells in 
nasal and nasopharyngeal mucosa in the case of the isolated post nasal 
drip syndrome. The fact must be mentioned that the control group 
patients nasal and nasopharyngeal mucosa samples contained less 
CgA immunopositive cells in comparison with the main group patients. 
 
CONCLUSIONS 
The main histological changes in the patients with the isolated post nasal 
drip syndrome are the thickened basal membrane, the hyperplasia of 
basal cells, the pronounced hyperplasia of mucosal glands, the sclerosis 
of small arterioles. The main neuropeptides that are found in nasal and 
nasopharyngeal mucosa samples are PGP 9.5, the vasoactive intestinal 
peptide, the neuropeptide Y and chromogranin in the post nasal drip 
syndrome group.  There is an imbalance of common neuropeptide-
containing innervations, mainly sympathic nerves, the precursors of 
neuropeptides – chromogranins in the nasopharyngeal mucosa of the 
patients with the post nasal drip syndrome. SP and CGRP are not the 
most characteristic neuropeptides in the case of the post nasal drip 
syndrome pathogenesis.  402  G. Sumeraga, M. Pilmane 
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